You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Paper-based Rapid Diagnostics for Early Dental Caries Prediction at the Chairside

    SBC: PHASE DIAGNOSTICS LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Dental caries is the single most common affliction across the globe affecting billion people The current process of identifying dental caries involves examining caries formation by naked eyes or X ray during routine checkups Once identified surgical restorative procedures are used to drill out the decay portion of the tooth an filled with synthetic mate ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications

    SBC: ARIMA GENOMICS, INC.            Topic: 172

    DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Alzheimer s diseaseADis an immense national public health burdenIt is theth leading cause of death in the US with overmillion Americans sufferingand costs of over $billion in health care and related expensesThis patient population is expected to almost triple over the nextyearsDespite this urgent needthere are currently no disease modifying agents approvedNeuron loss is the only physiological phen ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Silica-Based Organic Polymer for Ambient Ionization Mass Spectrometry

    SBC: Prosolia, Inc.            Topic: NIGMS

    DESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Novel noninvasive diagnostic technology for dynamic imaging of mitochondrial bioenergetics in breast cancer patients

    SBC: ROBIN MEDICAL INC            Topic: 102

    Summary Breast cancer is the second most common and the major cause of cancer related death of women in the USA The last decade has witnessed major advancement of therapeutic drugs and tools while noninvasive diagnostic imaging tools to measure interventions received much less attention Currently the mainstay of noninvasive imaging in breast cancer relies primarily on anatomic imaging Metabol ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government